AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual MeetingBusiness Wire · Oct 8, 2026
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026Business Wire · Oct 1, 2026
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of “Moderate Buy” from AnalystsDefense World · Oct 1, 2026
ABCL Stock Surges 121% in 3 Months: Here's What You Need to KnowZacks Investment Research · Sep 22, 2026
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026Business Wire · Sep 16, 2026
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026Business Wire · Sep 2, 2026AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.16 | -$0.18 | Miss |
| May 11, 2026 | -$0.22 | -$0.14 | Beat |
| Feb 24, 2026 | -$0.18 | -$0.03 | Beat |
| Nov 6, 2025 | -$0.17 | -$0.19 | Miss |
| Aug 7, 2025 | -$0.17 | -$0.12 | Beat |
| May 8, 2025 | -$0.17 | -$0.15 | Beat |